| Date | Title | | | 05/08/13 | Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2013 Health Care Conference| PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 8, 2013--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that
James Scibetta, chief financial officer of Pacira Pharmaceuticals, is
scheduled to present at the Bank of America Merrill Lynch 2013 Health
Care Conference on Wednesday, May 15, 2013, at 5:00 p.m. PT at the
Encore at the Wynn in Las Vegas. Mr. Scibetta is expected to present an
overview of the company.
A live audio webc... |
|  | | 05/08/13 | Pacira Pharmaceuticals, Inc. Reports $10.4 Million in First Quarter EXPAREL Revenue and Full First Quarter 2013 Financial Results| Company Will Host Conference Call Today at 9 a.m. ET
PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 8, 2013--
Pacira
Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced consolidated
financial results for the quarter ended March 31, 2013 and provided
updates on the commercial launch of EXPAREL®
(bupivacaine liposome injectable suspension) for postsurgical pain in
the United States.
“We saw a solid quarter in what was the fourth quarter ... |
| | | 05/06/13 | Two New Studies Support Use of EXPAREL via Infiltration Into the Transversus Abdominis Plane for Postsurgical Pain Control| Data Presented at Annual Meetings of Leading Regional Anesthesia
Societies Demonstrate Analgesia for Up to 72 Hours and High Patient
Satisfaction
PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 6, 2013--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced findings from
two new studies supporting the use of EXPAREL® (bupivacaine
liposome injectable suspension) infiltrated into the transversus
abdominis plane for postsurgical pain managem... |
| | | 05/01/13 | Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call| PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 1, 2013--
Pacira
Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial
results for the company’s first quarter ended March 31, 2013, will be
released before the market opens on Wednesday, May 8, 2013. The Pacira
management team will host a conference call to discuss the company’s
financial results and recent and upcoming developments on Wednesday, May
8, 2013, at 9 a.m. ET. The call can be acces... |
| | | 04/25/13 | New Published Analysis Finds Opioid-Related Adverse Events Increase Hospital Stays, Costs of Care and Risks of Readmission and Mortality| Retrospective Study Published in Pharmacotherapy Identifies
Advanced Age, Obesity, Pre-Surgery Opioid Use and Comorbid Conditions as
Predictive Risk Factors for Adverse Events
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 25, 2013--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the publication
of findings from a retrospective analysis of more than 37,000 patients
who underwent common inpatient surgeries at a large, 26-hospital
h... |
| | | 04/12/13 | New Data Support the Benefits of EXPAREL for Postsurgical Analgesia Following Aesthetic Plastic Surgery Procedures| Results Presented at American Society for Aesthetic Plastic Surgery
Meeting Show Patients Treated with EXPAREL Reported Low Pain Scores,
High Satisfaction and Minimal Opioid Use
NEW YORK--(BUSINESS WIRE)--Apr. 12, 2013--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results from
EXCLAIM, its Phase 4 prospective, observational study to assess the use
of EXPAREL® (bupivacaine liposome injectable suspension) for
postsurgical ... |
| | | 04/05/13 | Pacira Pharmaceuticals, Inc. to Close The NASDAQ Stock Market on April 8, 2013| PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 5, 2013--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that
David Stack, president and chief executive officer of Pacira
Pharmaceuticals, will close The NASDAQ Stock Market on Monday, April 8,
2013, in celebration of the one-year anniversary of the commercial
launch of EXPAREL® (bupivacaine liposome injectable suspension). Members
of the Pacira team will join Mr. Stack at the ceremony at the N... |
| | | 03/27/13 | Analysis of Postsurgical Pain Management Finds Opioid-Related Adverse Events Drive Longer Hospital Stays, Greater Cost and Higher Likelihood of Readmission| Retrospective Study Published in Journal of Pain and Palliative
Care Pharmacotherapy Utilized National Hospital Database and Assessed
Nearly 320,000 Surgeries
PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 27, 2013--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced data from a
large-scale analysis of a national database of patients from 380
hospitals in the United States who underwent 319,898 inpatient surgeries
and received opioids... |
| | | 03/07/13 | Pacira Pharmaceuticals, Inc. Reports 2012 Financial Results | PARSIPPANY, N.J.--(BUSINESS WIRE)--Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced consolidated 2012 financial results and provided updates on the commercial launch of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States.
"The launch of EXPAREL continues to go well. Weekly growth in new customers and continued expansion in hospitals that have gained experience with the product support our belief that EXPAREL provides a significant opportun... |
| | | 03/06/13 | Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference| PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 6, 2013--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that
David Stack, president and chief executive officer of Pacira
Pharmaceuticals, is scheduled to present at the Barclays Global
Healthcare Conference on Wednesday, March 13, 2013, at 2:30 p.m. ET at
the Loews Hotel in Miami. Mr. Stack is expected to present an overview
of the company.
A live audio webcast of the Pacira... |
| | | 02/28/13 | Pacira Pharmaceuticals, Inc. Announces Timing for 2012 Financial Results Webcast and Conference Call| PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 28, 2013--
Pacira
Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial
results for the company’s fourth quarter and year ended December 31,
2012, will be released before the market opens on Thursday, March 7,
2013. The Pacira management team will host a conference call to discuss
the company’s financial results and recent and upcoming developments on
Thursday, March 7, 2013, at 9 a.m. ET. T... |
| | | 02/25/13 | Pacira Pharmaceuticals, Inc. to Present at the Cowen and Company 33rd Annual Health Care Conference| PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 25, 2013--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that David
Stack, president and chief executive officer of Pacira Pharmaceuticals,
is scheduled to present at the Cowen and Company 33rd Annual
Health Care Conference on Monday, March 4, 2013, at 4:10 p.m. ET at the
Boston Marriott Copley Place in Boston. Mr. Stack is expected to present
an overview of the company.
A li... |
| | | 01/17/13 | Pacira Pharmaceuticals, Inc. Announces Pricing of $110 Million Private Offering of Convertible Senior Notes| PARSIPPANY, N.J.--(BUSINESS WIRE)--Jan. 17, 2013--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) (the “Company”) today announced
that it has priced its private offering of $110 million in aggregate
principal amount of its 3.25 percent Convertible Senior Notes due 2019.
The Company has also granted the initial purchasers a 30-day option to
purchase up to an additional $10 million in aggregate principal amount
of the notes on the same terms and co... |
| | | 01/15/13 | Pacira Pharmaceuticals, Inc. Announces Proposed Offering of $100 Million of Convertible Senior Notes| PARSIPPANY, N.J.--(BUSINESS WIRE)--Jan. 15, 2013--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) (the “Company”) today announced
that it proposes to offer $100 million of aggregate principal amount of
its convertible senior notes due 2019, subject to market conditions and
other factors. The notes are to be offered and sold only to qualified
institutional buyers pursuant to Rule 144A under the Securities Act of
1933, as amended. The notes will be... |
| | | 12/18/12 | New Publication Suggests Higher Opioid Use in the Postsurgical Setting May Be Linked to Extended Hospital Stay and Increased Cost of Care| PARSIPPANY, N.J.--(BUSINESS WIRE)--Dec. 18, 2012--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that the full
findings from the regional health system analysis conducted by Barnabas
Health to quantify the relationship between opioid use, total hospital
charges and patient length of stay (LOS) were published in Hospital
Pharmacy. This study demonstrated that in addition to increased
hospital charges, patients undergoing total abd... |
| | | 12/06/12 | Pacira Pharmaceuticals, Inc. and Aratana Therapeutics Inc. Enter into Global Licensing Agreement for Development and Commercialization of Bupivacaine Liposome Injectable Suspension for Animal Health Indications| PARSIPPANY, N.J. & KANSAS CITY, Kan.--(BUSINESS WIRE)--Dec. 6, 2012--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) and Aratana
Therapeutics Inc. today announced a global licensing agreement for
the development and commercialization of bupivacaine liposome injectable
suspension for animal health indications. Under the agreement, Aratana
will develop and seek approval for the use of the product in veterinary
surgery to manage postsurgical pai... |
| | | 11/20/12 | New Data Demonstrate Reduction in Opioid Use, Hospital Cost and Length of Stay with EXPAREL as the Foundation of a Multimodal Regimen|
Results published in the Journal of Pain Research compare cost
of care between standard opioid-based regimen and EXPAREL-based
multimodal regimen for postsurgical pain management
PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 20, 2012--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that results
from the first IMPROVE study to complete its prospective Phase 4
clinical program were published in the online version of the Journal
... |
| | | 11/20/12 | Pacira Pharmaceuticals, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference| PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 20, 2012--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that David
Stack, president and chief executive officer of Pacira Pharmaceuticals,
is scheduled to present at the 24th Annual Piper Jaffray Healthcare
Conference at The New York Palace Hotel on Tuesday, November 27, at 2
p.m. ET. Mr. Stack is expected to present an overview of the company.
A live audio webcast of the Pacira pr... |
| | | 11/13/12 | New Data Supporting Use of EXPAREL via Infiltration into the Transversus Abdominis Plane Presented at 11th Annual American Society of Regional Anesthesia and Pain Medicine Meeting|
Survey Demonstrating Continued Under-Management of Postsurgical Pain
Also Presented
PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 13, 2012--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the first data
presentation supporting the use of EXPAREL®
(bupivacaine liposome injectable suspension) infiltrated into the
transversus abdominis plane (TAP) for postsurgical pain management. TAP
infiltration is being increasingly utili... |
| | | 11/08/12 | Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference|
Presentation to be Webcast at 9:20 a.m. GMT on Thursday, November 15
PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 8, 2012--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that David
Stack, president and chief executive officer of Pacira Pharmaceuticals,
is scheduled to present at the Jefferies 2012 Global Healthcare
Conference in London on Thursday, November 15 at 9:20 a.m. GMT (4:20
a.m. ET). Mr. Stack is expected to present a... |
| | | 11/01/12 | Pacira Pharmaceuticals, Inc. Reports $4.6 Million in Third Quarter EXPAREL® Revenue and Full Third Quarter 2012 Financial Results|
Company Will Host Conference Call Today at 9 a.m. ET
PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 1, 2012--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced consolidated
financial results for the quarter ended September 30, 2012 and provided
updates on the commercial launch of EXPAREL®
(bupivacaine liposome injectable suspension) for postsurgical pain in
the United States.
“We launched EXPAREL in April and have suc... |
| | | 10/25/12 | Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call| PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 25, 2012--
Pacira
Pharmaceuticals, Inc (NASDAQ: PCRX) today announced that financial
results for the company's third quarter ended September 30, 2012, will
be released before the market opens on Thursday, November 1, 2012. The
Pacira management team will host a conference call to discuss the
company's financial results and recent and upcoming developments on
Thursday, November 1, 2012, at 9 a.m. ET. The ... |
| | | 10/18/12 | Richard A. Baxter, M.D., Receives OR Excellence Award for Use of EXPAREL®| Award recognizes plastic surgeon for "Best Use of Opioid Alternatives"
PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 18, 2012-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that prominent Seattle-based plastic surgeon Richard A. Baxter, M.D., FACS was recognized by Outpatient Surgery magazine for his use of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain management. The award for "Best Use of Opioid Alternatives" will be presented during the OR Excellence C... |
| | | 10/08/12 | EXPAREL® as the Foundation of a Multimodal Regimen Achieves Statistical Significance in All Primary Endpoints, Including a 60 Percent Reduction in Length of Hospital Stay|
IMPROVE trial compares the cost of care between a standard
opioid-based regimen and an EXPAREL-based multimodal regimen for
postsurgical pain management
PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 8, 2012--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced topline results
from the first completed IMPROVE study in its prospective Phase 4
clinical program. The study was designed to compare the difference in
three primary end... |
| | | 09/25/12 | Pacira Pharmaceuticals, Inc. Launches EXPAREL® Pivotal Nerve Block Trial|
First patient enrolled in two-part study to assess the safety and
efficacy of EXPAREL in femoral nerve block
PARSIPPANY, N.J.--(BUSINESS WIRE)--Sep. 25, 2012--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced initiation of
its Phase 2/3 pivotal trial of EXPAREL®
(bupivacaine liposome injectable suspension) administered as a
single-dose injection femoral nerve block for total knee arthroplasty
surgery. Results ... |
| | | 09/12/12 | Pacira Pharmaceuticals, Inc. to Present at the UBS Global Life Sciences Conference|
Presentation to be Webcast at 4:30 pm ET on Wednesday, September 19th
PARSIPPANY, N.J.--(BUSINESS WIRE)--Sep. 12, 2012--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that David
Stack, president and chief executive officer of Pacira Pharmaceuticals,
is scheduled to present at the UBS Global Life Sciences Conference at
the Grand Hyatt New York on Wednesday, September 19 at 4:30 p.m. ET. Mr.
Stack is expected to present an ... |
| | | 09/05/12 | Reduced Pain, Opioid Use, and Opioid-Related Adverse Events in Patients Receiving EXPAREL® Compared With Patients Receiving Bupivacaine HCl as a Component of Multimodal Therapy|
Results from Pooled Analysis of More than 900 Patients Published
Online in Current Medical Research and Opinion
PARSIPPANY, N.J.--(BUSINESS WIRE)--Sep. 5, 2012--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the publication
of results from a pooled analysis of nine clinical trials across five
surgical models that compared cumulative pain scores, opioid consumption
and occurrence of opioid-related adverse events (ORAEs) fo... |
| | | 08/09/12 | Pacira Pharmaceuticals, Inc. Reports $2.3 Million in Second Quarter EXPAREL® Revenue and Full Second Quarter 2012 Financial Results|
Company Will Host Conference Call Today at 9 a.m. ET
PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 9, 2012--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced consolidated
financial results for the quarter ended June 30, 2012 and provided
updates on the commercial launch of EXPAREL®
(bupivacaine liposome injectable suspension) for postsurgical pain in
the United States.
“With our first quarter of EXPAREL sales behind... |
| | | 08/07/12 | Pacira Pharmaceuticals, Inc. to Present at the Wedbush PacGrow 2012 Life Sciences Management Access Conference| PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 7, 2012--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that David
Stack, president and chief executive officer of Pacira Pharmaceuticals,
is scheduled to present at the Wedbush PacGrow 2012 Life Sciences
Management Access Conference on Tuesday, August 14, 2012, at 8:35 a.m.
ET at Le Parker Meridien in New York. Mr. Stack is expected to present
an overview of the company.
A l... |
| | | 07/31/12 | Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2012 Financial Results Webcast and Conference Call| PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 31, 2012--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that financial
results for the company's second quarter ended June 30, 2012, will be
released before the market opens on Thursday, August 9, 2012. The Pacira
management team will host a conference call to discuss the company's
financial results and recent and upcoming developments on Thursday,
August 9, 2012, at 9 a.m. ET. The call ca... |
| | | 06/05/12 | New Data Quantifying the Effects of Opioid Use on Patient Care and Economic Outcomes Presented at Key Medical Meetings|
Impact of Opioid-Related Adverse Drug Events on Total Hospital Cost
Presented at American Society of Colon and Rectal Surgeons (ASCRS)
Meeting
Impact of Opioid Use and Ileus Presented at International Society for
Pharmacoeconomics and Outcomes Research (ISPOR) Meeting
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jun. 5, 2012--
Pacira
Pharmaceuticals,
Inc. (NASDAQ: PCRX) today announced new data that demonstrate
opioid-relat... |
| | | 05/29/12 | Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference| PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 29, 2012--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that David
Stack, president and chief executive officer of Pacira Pharmaceuticals,
is scheduled to present at the Jefferies 2012 Global Healthcare
Conference on Monday, June 4, 2012, at 10:00 a.m. ET in New York. Mr.
Stack is expected to present an overview of the company.
A live audio webcast of the Pacira presentation can be... |
| | | 05/21/12 | Pacira Pharmaceuticals, Inc. to Be Added to NASDAQ Biotechnology Index| PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 21, 2012--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it has
been selected for inclusion in the NASDAQ Biotechnology Index® (NASDAQ:
NBI) effective today. The National Biotechnology Index is designed to
track the performance of biotechnology or pharmaceutical companies
listed exclusively on the NASDAQ Global Select Market or on the NASDAQ
Global Market that meet eligibility criteria... |
| |
|
